Biotech 2050 Podcast

Biotech 2050 Podcast

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

Den här podcasten är hämtad från ett öppet RSS-flöde och publiceras inte av Podme. Den kan innehålla reklam.

Avsnitt(263)

102. Vanquishing Parkinson's Disease, Jim Sullivan, PhD, Co-founder & CEO, Vanqua Bio

102. Vanquishing Parkinson's Disease, Jim Sullivan, PhD, Co-founder & CEO, Vanqua Bio

Dr. Sullivan is co-founder and CEO of Vanqua. In addition, he has been a Venture Partner with Orbimed since January 2019. Previously, he was the Vice President of Research at Abbvie where he was respo...

11 Maj 202222min

101. Revolutionizing genetic medicine, Paula Soteropoulos, Chairman of the Board, Ensoma

101. Revolutionizing genetic medicine, Paula Soteropoulos, Chairman of the Board, Ensoma

Paula Soteropoulos brings to Ensoma more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization with P&L acco...

4 Maj 202229min

100. Disruptive forces in biotech, Jake Becraft, Lex Rovner, Josh Mandel-Brehm, & Nabiha Saklayen

100. Disruptive forces in biotech, Jake Becraft, Lex Rovner, Josh Mandel-Brehm, & Nabiha Saklayen

Jake Becraft is co-founder and CEO of Strand Therapeutics, an emerging biotechnology company at the forefront of mRNA therapeutics. With colleagues at MIT’s Synthetic Biology Center, he led the develo...

27 Apr 20221h 5min

99. Precision medicine for sepsis, Tim Sweeney, Co-Founder and CEO, Inflammatix, Inc.

99. Precision medicine for sepsis, Tim Sweeney, Co-Founder and CEO, Inflammatix, Inc.

Tim Sweeney, MD, PhD, is co-founder and CEO of Inflammatix. Tim has extensive experience in medical practice (general & trauma surgery), bench research, and bioinformatics / machine learning. While tr...

20 Apr 202219min

98. Brain health disorders, Al Robichaud, Ph.D., CSO, Sage Therapeutics

98. Brain health disorders, Al Robichaud, Ph.D., CSO, Sage Therapeutics

Al leads teams in early-stage discovery up through non-clinical development, identifying new drug candidates for advancement into clinical research. Al joined Sage as CSO in 2011, with more than 20 ye...

13 Apr 202218min

97. Patient driven treatments in rare diseases, Stuart Peltz, Founder & CEO, PTC Therapeutics

97. Patient driven treatments in rare diseases, Stuart Peltz, Founder & CEO, PTC Therapeutics

Dr. Stuart Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the Board of Directors since the company’s inception. Under his leadership, PTC has grown ...

6 Apr 202228min

96. Obesity & rare disease, Patrick Kleyn, SVP and Head of Translational R&D,Rhythm Pharmaceuticals

96. Obesity & rare disease, Patrick Kleyn, SVP and Head of Translational R&D,Rhythm Pharmaceuticals

Patrick Kleyn joined Rhythm in 2018 with over 25 years’ experience in human genetics and genomics, and he was named as head of TRAD in 2021. Prior to joining Rhythm, Patrick has held leadership roles ...

30 Mars 202220min

95. Gene writing, Dr. Jake Rubens, Co-Founder & CIO, Hari Pujar, COO, Tessera Therapeutics

95. Gene writing, Dr. Jake Rubens, Co-Founder & CIO, Hari Pujar, COO, Tessera Therapeutics

Jacob(Jake)Rubens, Co-Founder, Chief Innovation Officer Jake is Co-Founder and Chief Innovation Officer of Tessera Therapeutics, as well as a Principal at Flagship Pioneering. Jake joined Flagship Pi...

23 Mars 202225min

Populärt inom Vetenskap

dumma-manniskor
p3-dystopia
allt-du-velat-veta
kapitalet-en-podd-om-ekonomi
ufo-sverige
medicinvetarna
halsorevolutionen
det-morka-psyket
rss-vetenskapsradion
ufo-sverige-2
svd-nyhetsartiklar
sexet
rss-spraket
rss-ufobortom-rimligt-tvivel
paranormalt-med-caroline-giertz
bildningspodden
ideer-som-forandrar-varlden
vetenskapsradion
rss-odla
rss-vetenskapsradion-2